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Osteoporotic fractures are a major cause of morbidity and mortality in ageing populations. Osteoporosis, defined as
low bone mineral density (BMD) and associated fractures, have significant genetic components that are largely
unknown. Linkage analysis in a large number of extended osteoporosis families in Iceland, using a phenotype that
combines osteoporotic fractures and BMD measurements, showed linkage to Chromosome 20p12.3 (multipoint allele-
sharing LOD, 5.10; p value, 6.3 3 10
 7), results that are statistically significant after adjusting for the number of
phenotypes tested and the genome-wide search. A follow-up association analysis using closely spaced polymorphic
markers was performed. Three variants in the bone morphogenetic protein 2 (BMP2) gene, a missense polymorphism
and two anonymous single nucleotide polymorphism haplotypes, were determined to be associated with osteoporosis
in the Icelandic patients. The association is seen with many definitions of an osteoporotic phenotype, including
osteoporotic fractures as well as low BMD, both before and after menopause. A replication study with a Danish cohort
of postmenopausal women was conducted to confirm the contribution of the three identified variants. In conclusion,
we find that a region on the short arm of Chromosome 20 contains a gene or genes that appear to be a major risk
factor for osteoporosis and osteoporotic fractures, and our evidence supports the view that BMP2 is at least one of
these genes.
Introduction
Osteoporosis is a common disease characterized by low
bone mineral density (BMD) and manifesting clinically with
fragility fractures of the hip, spine, and other skeletal sites. It
is generalized in its most common form, affecting the elderly,
both sexes, and all racial groups, although postmenopausal
women are at highest risk (Peacock et al. 2002). There are
over 1 million osteoporotic fractures per year in the United
States alone, primarily in women, and the direct medical costs
exceed US$10 billion annually (Ray et al. 1997). One of the
challenges in medicine today is to identify those who are at
high risk for osteoporosis before they suffer fractures or lose
signiﬁcant bone mass.
Various factors may distinguish those who develop osteo-
porotic fractures from those who do not, but the most
important appears to be BMD values, both attained in young
adults as well as with increasing age. Firstly, peak bone mass
(the highest BMD, attained in young adulthood) may
represent an important measure of predisposition to
osteoporosis. Secondly, the rate of postmenopausal bone loss
may be higher in some than in others. There is abundant
evidence for a genetic contribution to BMD variation,
especially the peak bone mass, but a large genetic contribu-
tion to BMD at older ages has also been demonstrated.
Environmental factors such as diet, medications, and physical
activity may also determine the ultimate BMD. Furthermore,
the rate of bone loss, bone size and structure, and propensity
to fall are all factors with genetic components and all
contribute to the risk of osteoporotic fractures beyond
BMD itself (Peacock et al. 2002).
Numerous candidate genes, selected on the basis of current
knowledge of bone biology, have been tested for association
to BMD and to osteoporotic fractures. A polymorphism in the
Sp1 transcription factor-binding site in the ﬁrst intron of the
collagen 1A1 (COL1A1) gene has shown the most consistent
association to osteoporosis, although varying between study
groups and populations (Efstathiadou et al. 2001; Mann et al.
2001). A few genome-wide linkage scans have been reported
by those searching for new genes contributing to BMD
variation and skeletal geometry (Devoto et al. 1998; Niu et al.
1999; Koller et al. 2000, 2001; Deng et al. 2002; Karasik et al.
2002; Wilson et al. 2003), and several linkage studies analyzing
only speciﬁc chromosomal locations have also been con-
ducted (Spotila et al. 1996; Koller et al. 1998; Duncan et al.
1999; Carn et al. 2002). However, none of the loci reported
have met criteria for genome-wide signiﬁcance for linkage,
and the osteoporosis genes corresponding to these regions
have not yet been isolated. The roles in the common forms of
Received July 28, 2003; Accepted October 9, 2003; Published November 3, 2003
DOI: 10.1371/journal/pbio.0000069
Copyright:  2003 Styrkarsdottir et al. This is an open-access article distributed
under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited.
Abbreviations: BMD, bone mineral density; BMP2, bone morphogenetic protein 2;
cM, centimorgan; COL1A1, collagen 1A1; df, degree of freedom; EST, expressed
sequence tag; FP–TDI, fluorescent polarization template-directed dye-terminator
incorporation; GWS, genome-wide scan; LD, linkage disequilibrium; LOD, logarithm
of the odds; LRP5, lipoprotein receptor-related protein 5; PCR, polymerase chain
reaction; RR, relative risk; RT–PCR, reverse transcript polymerase chain reaction; SD,
standard deviation; SNP, single nucleotide polymorphism
Academic Editor: Lon Cardon, University of Oxford
*To whom correspondence should be addressed. E-mail: unnur.styrkarsdottir@
decode.is (US), gunnars@landspitali.is (GS), kari.stefansson@decode.is (KS)
[These authors contributed equally to this work.
PLoS Biology | http://biology.plosjournals.org Volume 1 | Issue 3 | Page 351
PLoS BIOLOGYosteoporosis of the genes encoding low-density lipoprotein
receptor-related protein 5 (LRP5) and the osteoclast-speciﬁc
vacuolar proton pump (TCIRG1) on Chromosome 11q12-13,
which cause three Mendelian BMD-related diseases/traits
(Frattini et al. 2000; Kornak et al. 2000; Gong et al. 2001;
Boyden et al. 2002; Little et al. 2002; van Hul et al. 2002), also
remain to be shown.
Here we present the results of the genealogic approach
applied to osteoporosis in Iceland (Gulcher et al. 2001a,
2001b). The aim of the study described here was to ﬁnd genes
contributing to the risk of osteoporotic fractures and its
immediate precursor, low BMD. However, instead of simply
mapping a quantitative trait locus for BMD itself, we chose to
focus on the clinically most relevant manifestation of
osteoporosis, low BMD and osteoporotic fractures. Low
BMD is the single best predictor of osteoporotic fractures
(Marshall et al. 1996) and is most commonly used both as a
diagnostic criterion and as the basis for treatment. BMD is,
however, only a surrogate marker for osteoporotic fractures
and is inﬂuenced by many factors. Furthermore, osteoporotic
fractures also occur in individuals who do not fall within low
BMD range. Therefore, we deﬁned a novel mixed phenotype
for osteoporosis for use in this study, combining low BMD
values and osteoporotic fractures themselves. By combining
age-matched BMD values at both the hip and the spine in the
same analysis, we attempted to ﬁnd the underlying genetic
basis for generalized osteoporosis, instead of a skeletal site-
speciﬁc osteoporosis. Furthermore, although BMD is nor-
mally distributed at all ages in the population and is therefore
a quantitative trait with presumed polygenic inheritance, it
does not necessarily imply that the genes controlling low
BMD in families, signiﬁcant enough to lead to osteoporotic
fractures, are the same as those that control the normal
distribution of BMD in the population. Therefore, an
affected-only approach to linkage analysis, using BMD values
below a certain cut-off in combination with osteoporotic
fractures, might be an effective approach to the mapping of
genes that predispose to osteoporosis. We found highly
signiﬁcant linkage to Chromosome 20p using this approach,
discovered variants in the bone morphogenetic protein 2
gene (BMP2) that are associated with osteoporosis, and
conﬁrmed the BMP2 association in a cohort of Danish
osteoporosis patients.
Results
Linkage Analysis
Linkage analysis, using multipoint allele-sharing methods,
was conducted for four phenotype criteria in 207 extended
Icelandic osteoporotic families, containing 1,323 study
individuals (see Materials and Methods). Descriptions of the
phenotypes and pedigree sets along with a summary of the
linkage results are provided in Table 1. We ﬁrst investigated
osteoporosis as it is broadly deﬁned (moderate pedigree set).
This is the most generalized osteoporosis phenotype, includ-
ing individuals with a hip and spine BMD approximately one
standard deviation (SD) or more below the average and/or
those with osteoporotic fractures and/or those receiving
bisphosphonate treatment for osteoporosis. The most prom-
inent peak was on Chromosome 20 at D20S905 (19.90 cM)
with an allele-sharing logarithm of the odds (LOD) score of
3.39 (p value, 4.2 3 10
 5), with four other locations, achieving
a LOD score of 1.5 or greater: 16q, two on 18p, and 21q
(Figure 1; Table 1).
We next used a deﬁnition of a more severe phenotype, with
only individuals in the lower 10th percentile of BMD as
affected members, but including fracture patients and
patients treated for osteoporosis as in the previous run.
The most striking feature of this scan was the increase in the
peak on Chromosome 20p (Figure 1) that was again at
D20S905, but now with a LOD score of 4.93. Two new LOD
peaks were observed on Chromosomes 6p and 17p (Figure 1;
Table 1). Compared to the LOD score peaks we had observed
when analyzing the moderate pedigree set, for the severe
pedigree set both of the peaks on 18p were greatly
attenuated, the peak on 16p persisted, and the peak on 21p
dropped by about a LOD of 0.5. Two additional analyses were
conducted, one considering only hip osteoporosis (hip
pedigree set) and the other considering only spine osteopo-
rosis (spine pedigree set). In both cases, the strongest linkage
was to Chromosome 20p, but with slightly higher LOD score
(3.18) for the hip analysis (Figure 1).
The results at Chromosome 20p were encouraging, so we
decided to genotype 30 additional markers in the region in
order to increase the information on identity by descent
sharing. At this increased ﬁne-mapping density, the informa-
tion on sharing was over 95% and the LOD score rose to 5.10
(p value, 6.3 3 10
 7) at D20S194 (20.35 cM) in the severe
phenotype. The LOD score increased for all phenotypes, to
3.99, 3.99, and 3.43 for the moderate, the hip, and the spine
pedigree sets, respectively. After applying a Bonferonni
adjustment for the four phenotypes tested, the p value for
linkage is 1.6 3 10
 6, which is genome-wide signiﬁcant
according to the dense marker threshold for multipoint
genome scans (Lander and Kruglyak 1995).
Linkage Disequilibrium Mapping, Association Analysis,
and BMP2 Variants
We investigated a 6.6 cM region surrounding our linkage
peak that corresponds to a 1.7 Mb segment. This region,
which includes up to a drop of 1 in LOD score from the
linkage peak on the centromeric side and slightly less on the
telomeric side, contains six known genes: BMP2, CHGB,
LOC51605, C20orf154, C20orf155, and C20orf42 (Figure 2B).
The BMP2 gene is a strong candidate gene, based on its role
in bone formation and osteoblast differentiation (Wozney et
al. 1988; Katagiri et al. 1994; Fujii et al. 1999). However,
expression analysis showed that four of the genes in the
region are expressed in bone marrow or in an osteoblast cell
line (BMP2, C20orf42, C20orf154, and CHGB). Therefore, the
expression data did not help us narrow the list of candidate
genes.
To decide which gene in the focused region is most likely to
contribute to osteoporosis, we performed a case–control
association study by typing many additional polymorphic
markers. We used the severe-linkage phenotype as affection
status and included all available genotyped patients, includ-
ing additional familial cases and sporadic cases, in the
analysis, 705 in total. BMP2 was our leading candidate, and
we genotyped two microsatellites and 15 single nucleotide
polymorphisms (SNPs) in the 15 kb region containing BMP2.
The other ﬁve genes clustered in a 220 kb region. For this
region of genes, we genotyped nine microsatellites and 26
SNPs. We genotyped additional markers across the entire
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BMP2 as an Osteoporosis Susceptibility GeneTable 1. Genome-Wide Scan Results and Fine-Mapping on Chromosome 20p12
Phenotype ###
5q 6p 10p 16q 17p 18p 21p 20p12
fam aff rel D5S2040 D6S282 D10S1430 D16S488 D17S969 D18S63 D18S1163 D21S1899 GWS Fine-Mapping
Moderate 123 386 521 — — — 1.64 — 1.64 1.63 1.81 3.39 3.99
Severe 95 261 470 — 2.06 — 1.83 2.02 — — — 4.93 5.10
Hip 99 268 493 — — 1.52 1.99 — — — — 3.18 3.99
Spine 97 367 435 1.56 — — 1.72 — 2.12 — — 2.89 3.43
The LOD scores above 1.5 and their genomic locations for any of four phenotypes analyzed using the genome-wide scan (GWS) framework marker set (1,100 microsatellite
markers) and fine-mapping markers on Chromosome 20p12 are shown. Included are the number of informative families (#fam) for each phenotype and numbero f
genotyped affected members (#aff) and relatives (#rel) in each analysis. The moderate, the hip, and the spine phenotypes include persons in the lower 16th percentile of
combined hip and spine BMD, hip BMD, or spine BMD, respectively. The severe phenotype includes persons in the lower 10th percentile of combined hip and spine BMD. All
BMD measurements are corrected for age, sex, and weight. The pedigree sets also include as affected those being treated for osteoporosis with bisphosphonates or having
had an osteoporotic fracture at the relevant locations: hip fracture in the hip pedigree set, vertebral fracture in the spine pedigree set, or any osteoporotic fracture in the
moderate or severe pedigree sets (see Materials and Methods). The number of those additional individuals who did not meet the BMD criteria alone for affection status were
3, 3, 30, and 20 for the hip, spine, moderate, and severe pedigree sets, respectively.
DOI: 10.1371/journal/pbio.0000069.t001
Figure 1. Framework Linkage Scan
Framework linkage scan using 1,100 microsatellite markers for the severe (black line), moderate (red line), hip (green line), and spine (blue line)
pedigree sets. The LOD score is on the y axis and the distance from the pter in Kosambi cM is on the x axis. Note that the LOD score scales are
the same for all chromosomes except Chromosome 20.
DOI: 10.1371/journal/pbio.0000069.g001
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BMP2 as an Osteoporosis Susceptibility Generegion in case there were other unidentiﬁed genes or
nongene regions associated with the disease. In total in the
1.7 Mb region, we genotyped 41 microsatellites, 99 SNPs that
are polymorphic in the Icelandic population (some of the
public SNPs are exonic), and 20 other SNPs that we identiﬁed
by screening all exons and ﬂanking intronic sequences of all
six genes or expressed sequence tag (EST) matches. Figure 2B
displays the location of the microsatellites and SNPs used in
this analysis relative to the gene locations. Single-marker
association and haplotype analyses showed the strongest
association to the region of the BMP2 gene (Figure 3). The
BMP2 gene appears to be the only gene within this region,
despite our extensive efforts to ﬁnd additional transcripts
(see below). Linkage disequilibrium (LD) analysis across the
Figure 2. The Chromosome 20p12 Linkage
Region
(A) Chromosome 20 linkage scan for the
narrower deﬁnition of osteoporosis (se-
vere). The LOD score is on the y axis and
the distance from pter in Kosambi cM is
on the x axis.
(B) Region under the linkage peak is
shown in more detail, including location
of microsatellite markers (STRs), loca-
tion of SNPs, and location of genes in the
region and their direction of transcrip-
tion. The legend bar indicates the
distance corresponding to 100 kb.
DOI: 10.1371/journal/pbio.0000069.g002
Figure 3. Association Analysis in the
Focused Region
Association results for one to four
consecutive microsatellite markers over
the 1.7 Mb region. Only haplotypes with
RRs over 1 are plotted. p Values are
given on the left and megabase (Mb)
locations at bottom.
DOI: 10.1371/journal/pbio.0000069.g003
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BMP2 as an Osteoporosis Susceptibility Generegion, including some SNPs added subsequently, identiﬁed
about ten blocks of LD, ranging from 10 kb to 250 kb in size.
Further blocks of LD are likely to exist in some gaps where no
polymorphic markers were found, but these locations tend to
be ‘‘gene-free.’’
In order to further understand the haplotype associations
and to search for functional variations or SNPs that might
capture the risk of osteoporosis, we sequenced the BMP2
gene in 188 patients and 94 controls. The sequenced region
covered the 15 kb containing the BMP2 gene, including all
exons, introns, and the promoter region, along with another
44 kb of DNA ﬂanking the gene. We genotyped all patients
and controls for 63 SNPs from among those identiﬁed within
the 59 kb region, including SNPs that we had used in this
region in the previous analysis. Three of the SNPs change
amino acids in BMP2: Ser37Ala, due to a T to G transversion
at nucleotide position 116 in exon 2; Ala94Ser, due to a G to
T transversion at nucleotide position 287 in exon 2; and
Arg189Ser, due to an A to T transversion at nucleotide
position 224 in exon 3. The Ala94Ser variant was only found
in one family. The Arg189Ser variant is very common and
does not show any association to osteoporosis on its own. The
Ser37Ala variant, however, changes a conserved amino acid
and shows signiﬁcant association to osteoporosis. It is a
relatively rare variant, with allele frequency ranging from
3.0% to 4.9% in patients, depending on the phenotype,
versus 0.8% in controls, yielding relative risks (RRs) in the
range of 3.8 to 6.3 (Table 2); four of the seven phenotypes
tested produce p values smaller than 0.001 after adjusting for
the relatedness of the affected (see Materials and Methods).
Given that Ser37Ala is only one of three missense variants
identiﬁed in BMP2, we consider this result statistically
signiﬁcant even with adjustment for multiple comparisons.
Since Ser37Ala is rare and can only account for a small
fraction of the affected, we believed there had to be other at-
risk variants of BMP2. Through our effort to search for these
other variants, we found three SNP haplotypes covering the
BMP2 gene that show the strongest association to osteopo-
rosis (Table 2; Figure 4A). The three haplotypes, hapA, hapB,
and hapC, deﬁned by a total of six SNPs, are essentially
independent of each other (pairwise R
2, less than 0.01). The
Ser37Ala variant, however, seems to have arisen on the
background of hapA so that every chromosome that carries
Ser37Ala also carries hapA, but not vice versa. Moreover, it
appears that the excess of hapA in the affected can be
explained by Ser37Ala; i.e., chromosomes with hapA but not
Ser37Ala do not have signiﬁcant excess in the affected versus
controls. The hapB is deﬁned by three SNPs—TSC0271643
(T), P9313 (T), and rs235764 (G)—and spans from within
intron 2 of BMP2 and 263 kb upstream of the gene, going
across LD blocks (Figure 4). The upstream SNP is in the
region of the most signiﬁcant single-point microsatellite
association. HapC is deﬁned by two SNPs, rs1116867 (A) and
D35548 (T), downstream of BMP2 and spans 18 kb (Figure 4).
HapC is entirely contained within one LD block. There is,
however, signiﬁcant LD between some markers across the
hapC LD block and the BMP2 LD block. BMP2 is the only
known or predicted gene within the segments spanned by the
two haplotypes, as previously noted.
To explore the role of Ser37Ala and hapB and hapC in
relation to various forms of osteoporosis, we used several
other osteoporotic phenotypes in the association analysis,
including osteoporotic fractures, whole-body BMD, and pre-
and postmenopausal BMD, each analyzed separately (see
Table 2). The Ser37Ala variant and hapC are associated with
all low BMD phenotypes and with osteoporotic fractures. In
fact, the RR for low BMD is higher in premenopausal women
than postmenopausal women, indicating that BMP2 may
inﬂuence the attainment of peak bone mass. HapB, on the
other hand, seems more associated with osteoporotic
fractures than with BMD phenotypes.
Removing patients who carry the Ser37Ala variant or the
disease-associated haplotypes from the linkage analysis,
leaving 152 affected in families informative for linkage, the
LOD score drops from 5.10 to 3.55. Hence, these variants
alone cannot account for the entire linkage signal. Even
taking into consideration that there is usually a substantial
upward bias in estimation of locus-speciﬁc effects from
genome scans (Goring et al. 2001), we believe there are likely
to be other variants, probably rare but possibly having very
high penetrance, which have yet to be identiﬁed. We also
cannot rule out that other genes in the region are conferring
osteoporosis risk independently or interacting with BMP2.
We have not yet determined the underlying functional
variations of disease-associated hapB and hapC. Most
importantly, as anonymous haplotypes, proper interpretation
of the statistical signiﬁcance of hapB and hapC has to take
multiple comparisons into account. By performing a random-
ization test (randomizing the patients and controls) for a
procedure that considers all haplotypes within the LD block
that contains hapC, the smallest adjusted p value is 0.003 for
whole-body BMD (see Table 2), 125 times larger than the
unadjusted p value of 2.4 3 10
 5. Since this adjusted p value
still has not taken into account the relatedness of the patients,
the multiple phenotypes tested, and the other LD blocks in
the region, we consider hapC at best marginally signiﬁcant
with the Icelandic data alone. HapB goes across LD blocks,
and the randomization procedure is performed by consider-
ing all possible haplotypes within the region spanned by those
blocks, leading to an even larger adjustment factor. As a
result, none of the adjusted p values for hapB are signiﬁcant
(see Table 2). Hence, instead of haplotypes already established
to confer increased risk, we considered hapB and hapC only
as candidate at-risk haplotypes, identiﬁed based on the
Icelandic material that required conﬁrmation from a
replication study.
Haplotype Confirmation in Danish Cohort
For replication, we used a cohort of Danish postmeno-
pausal women with persistently low BMD and a group of
Danish postmenopausal osteoporotic fracture patients. We
only typed those SNPs that comprised hapB and hapC as well
as the Ser37Ala variant. The results for the Danish study are
also shown in Table 2. For all six tests, two phenotypes times
three variants, the patients have a higher frequency of the
variant compared to the controls, and the estimated RRs are
overall comparable to those observed in the Icelanders.
However, the p values are higher in general due to the smaller
sample sizes of the Danish cohort. Nonetheless, hapC gives a p
value of 0.0038 for low BMD, which is signiﬁcant even after
adjusting for the six tests performed. The Ser37Ala missense
variant is nominally signiﬁcant for osteoporotic fractures,
with an estimated RR of 4.2, and hapB is nominally signiﬁcant
for low BMD, with an estimated RR of 2.1.
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BMP2 as an Osteoporosis Susceptibility GeneAnother way of handling the problem of testing multiple
variants is to consider them as a group. Deﬁne a composite
haplotype, hapX, as a chromosome that carries at least one of
either the Ser37Ala missense variant, hapB, or hapC. For the
Danish cohort, hapX is estimated to have a frequency of
16.3% in the low BMD patients versus 7.3% in controls,
giving a one-sided p value of 0.004 with an RR of 2.5. The
frequency of hapX in the osteoporotic fracture patients is
estimated to be 15.3%, giving a one-sided p value of 0.037
with an RR of 2.2.
Screening for Genes Other than BMP2 within the
Association Region
We investigated the presence of other genes besides BMP2
within the region covered by the disease-associated haplo-
types. All predicted exons and ESTs in the region were
considered potential exons in yet undiscovered genes.
Reverse transcript polymerase chain reaction (RT–PCR) was
performed using RNA from a fetal osteoblastic cell line and
bone marrow, where the PCR primers were designed so as to
connect adjacent exons of a particular predicted open
reading frame or ESTs. Several gene-prediction programs
were used, as well as comparisons to the syntenic mouse
region, which we sequenced. None of the predicted genes
gave us products using these sources of RNA. We therefore
conclude that the BMP2 gene is the only gene within the
region of the haplotype variants.
Discussion
We have mapped osteoporosis susceptibility to the short
arm of Chromosome 20 using linkage analysis in Icelandic
families. Case–control association analyses using ﬁrstly Ice-
landic samples and subsequently replicated with an inde-
pendent Danish cohort support BMP2 as the gene, or one of
the genes, in the region contributing to osteoporosis risk. We
applied a novel deﬁnition of the osteoporosis phenotype,
based on corrected BMD values at both the spine and the hip
in the same analysis (a more generalized osteoporosis) in
addition to including osteoporotic fractures. Hitherto,
osteoporotic fractures have not been used as a phenotype
in any linkage scan reported, neither on their own nor in
combination with BMD values. All previously reported
linkage studies were based on the use of BMD at speciﬁc
skeletal sites as a quantitative trait in the analysis. We want to
emphasize that we did not consider our approach to be
inherently superior, but rather a reasonable alternative that
seems to have worked in this instance. We have also observed
that pedigrees with low BMD are not a rarity in the
population, as has been suggested (Peacock et al. 2002); in
fact, the vast majority of probands in this study had close
relatives who, when measured, also turned out to have low
BMD. However, the skeletal site of low BMD could vary, not
necessarily being the same site among the relatives nor
among all members within a particular pedigree. This
observation is also consistent with our linkage results,
applying a combination of both the hip and the spine BMD
measurements in the same analysis. Our skeletal site-speciﬁc
linkage runs both conﬁrm the results on the Chromosome
20p locus and also show that there are other potential loci
that seem to be more site speciﬁc; however, the LOD scores at
these loci did not reach genome-wide signiﬁcance.
The linkage region on Chromosome 20 contains several
Figure 4. BMP2 Haplotype Region and LD
(A) The location of haplotypes, markers,
and the Ser37Ala missense variant is
shown in relation to the location of
BMP2 exons and to the LD blocks in (B).
(B) Two measures of LD are shown: D9
values on the upper-left side of the plot
and p values on the lower-right side.
Scales for the LD strength are provided
for both measures to the right. This
graph shows uniformly distributed SNPs
in a 370 kb region in and around the
BMP2 gene. The BMP2 block and the
next block downstream represent 53 kb.
DOI: 10.1371/journal/pbio.0000069.g004
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BMP2 as an Osteoporosis Susceptibility Genegenes. Expression analysis alone was not helpful in narrowing
the focus to a single gene. Four of the genes in the region are
expressed in an osteoblast cell line or in bone marrow (BMP2,
C20orf42, C20orf154, and CHGB). However, initial association
analysis did draw attention to the BMP2 gene, which is a
priori a strong candidate gene, based on its role in bone
formation and osteoblast differentiation (Wozney et al. 1988;
Katagiri et al. 1994; Fujii et al. 1999). Our analysis indicates
that the inﬂuence of BMP2 on the development of osteopo-
rosis is that on the attainment on peak bone mass, rather than
increased bone loss. The attainment of peak bone mass is a
part of the developmental process. The role of BMP2 in this
process is probably through stimulating the differentiation
and/or activity of osteoblasts. The number of differentiated
osteoblasts may be lower, or their BMP2-induced activity
lower, in individuals who attain low peak bone mass. The
nature of the underlying haplotype variations in the BMP2
gene is not evident, nor is the effect of the Ser37Ala missense
variant. The Ser37Ala variant changes an amino acid in the
precursor part of the protein, which might have an effect on
the stability of the latent dimer or might play a role in the
secretion or activation of the protein. Given the diverse role
of BMP2 (Wozney et al. 1990; Zhang and Bradley 1996;
Kanzler et al. 2000; Takazawa et al. 2000), variations in this
gene may have only subtle effects on its activity and most
probably in a spatially and temporally tissue-speciﬁc manner,
through regulation at the level of transcription, alternative
splicing, mRNA transport and stability, or translation.
Given the degree of multiple testing in the Icelandic cohort
and the fact that the identiﬁed at-risk variants cannot fully
account for the linkage signal, we could not be conﬁdent in
the results without conﬁrmation in an independent cohort.
Therefore, we evaluated the results we observed in Iceland by
testing the haplotype association and the Ser37Ala variant in
an independent cohort of Danish osteoporosis patients. The
variants have comparable frequencies and estimated risks in
this second European population, supporting the hypothesis
that the association of BMP2 with osteoporosis is not unique
to the Icelandic population. However, the replication sample
is only modest in size. Hence, we hope that the promising
results presented here will stimulate other replication studies,
necessary to further conﬁrm and to provide a more
comprehensive evaluation of the role of BMP2 in osteopo-
rosis. Moreover, even if all of our identiﬁed at-risk variants
were to be conﬁrmed in replication studies, the fact that they
cannot fully explain the linkage signal implies that there may
be other genes in the region also contributing to the linkage
signal or that there are other at-risk variants of BMP2 that
have yet to be identiﬁed.
The possibility of exploiting genes in the BMP signalling
pathway during osteoblast differentiation for new drug
targets in the treatment of osteoporosis was pointed out
previously (Mundy et al. 2001). Our results lend support to
this idea. Variants in BMP2 may also be useful in addressing
the unmet medical need of identifying those at increased risk
for osteoporosis and fractures.
Materials and Methods
Study subjects and phenotype. The study group was drawn from a
large number of individuals who have had BMD measurements at the
National University Hospital of Iceland. Individuals with age-matched
BMD (Z score) less than 1 SD below average were invited to participate
in the study. Spouses, children (18 years and older), parents, and
siblings of participating individuals were also invited to participate.
The BMD of all participants, including relatives, was determined
using dual-energy X-ray absorptiometry at the lumbar spine (L2–L4)
in posterior–anterior projection and at the total hip (proximal end of
femur) and whole body (QDR 4500A, Hologic, Waltham, Massachu-
setts, United States). Weight and height were measured at the time of
BMD measurement. All participants completed a detailed question-
naire regarding their medical history, menstrual period, current and
past medications, and history of all fractures and trauma. The BMD
values were corrected for sex and age to yield the standard Z score,
using reference data on 1,407 BMD measurements on randomly
collected individuals in Iceland who had not received therapy
inﬂuencing BMD, thus creating a population-speciﬁc reference for
corrections. We further corrected these Z scores for weight, which was
found to be a signiﬁcant variable, as has been reviewed by Reid (2002).
Data on osteoporotic fractures are mostly self-reported, collected
via a detailed questionnaire, but not further validated. Validation of
fractures through medical records (clinical history, X-rays, hospital
records) was, however, done for individuals who reported low-impact
fractures but had BMD values higher than 1 SD below average.
Osteoporotic fractures were deﬁned as low-impact vertebral com-
pression fractures, low-impact hip fractures, or low-impact fractures
at other sites if there were two or more such fractures. The lower age
limit for osteoporotic fractures was 40 y, and fractures of ﬁngers,
hands, toes, or feet were not included. We excluded as affected
subjects those with a history of considerable corticosteroid use (7.5
mg per day for 3 mo or more) or with menopause before the age of 40
y, but the excluded subjects could be used as relatives with unknown
status. Also, individuals who were suspected to suffer from diseases or
deﬁciencies that inﬂuence BMD were also excluded as affected. If
available, an early BMD measurement from before the beginning of
hormone replacement therapy or the treatment of bisphosphonates
was used.
There were 1,323 individuals with BMD measurements, corrected
for age, sex, and weight, as indicated above, and regardless of whether
the measurements were high or low, who formed the linkage cohort.
Pedigrees were identiﬁed using our genealogical database of Ice-
landers (Gulcher and Stefansson 2000) such that all cohort individuals
related at ﬁve or fewer meioses (ﬁve meioses separate relatives who
are between ﬁrst and second cousins) were in the same pedigree.
Families that were too large for the linkage software were split for
computational purposes. Linkage analysis was performed by deﬁning
an osteoporotic phenotype and considering only those meeting the
criteria as affected. Thus, for any particular analysis, only a subset of
the initial families were informative for linkage. Four pedigree sets,
each corresponding to a slightly different phenotype, were analyzed.
The phenotype descriptions, the number of families informative for
linkage, the number of affected members, and the number of
genotyped relatives in the families for these four pedigree sets are
displayed in Table 1. In the moderate pedigree set, there were 79
individuals being treated with bisphosphonates and 78 individuals
who had suffered an osteoporotic fracture; in the severe pedigree set,
there were 70 being treated and 73 with fractures; in the hip pedigree
set, there were 40 treated and ﬁve with fractures; and in the spine
pedigree set, there were 44 treated and ﬁve with fractures.
An additional 478 affected individuals were recruited for
association analysis, 109 men (mean age, 53.7 y) and 369 women
(mean age, 51.9 y). For the analysis of a particular phenotype, all
members of the linkage cohort with that phenotype were included
along with those having the phenotype in the additional set. The
entire association cohort across all phenotypes consisted of 957
individuals, 781 women and 176 men. The control group was
comprised of 710 randomly collected individuals from the general
population, 468 women and 242 men, in the age range of 30–85 y,
whose medical history was unknown. A subset of these groups, both
patients and controls, were typed for the Ser37Ala variant, since this
required sequencing for typing instead of our routine ﬂuorescent
polarization template-directed dye-terminator incorporation (FP–
TDI) assay for SNP typing (see below).
All participants gave informed consent, and both the National
Bioethics Committee and the Data Protection Commission of Iceland
approved the study. Personal identities associated with blood samples
and the Decode Genealogy Database were encrypted by the Data
Protection Commission, as previously described (Gulcher et al. 2000).
Danish cohort. The study group was selected from the PERF
(Prospective Epidemiological Risk Factors) study in Denmark (Bagger
et al. 2001). Two osteoporotic patient groups were analyzed: women
with BMD in the lowest 10th percentile of the weight-corrected Z
score at either the hip or the spine, both at baseline and at follow-up
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BMP2 as an Osteoporosis Susceptibility Genemeasurement, and a group of postmenopausal osteoporotic fracture
patients. The fracture group included women who had suffered two
or more low-impact osteoporotic fractures, meeting the same criteria
as described in the Icelandic material. The control group consisted of
women who had a weight-corrected Z score around the mean ( 0.8 to
0.8 SD), both at baseline and at follow-up, randomly picked.
Linkage analysis. A genome-wide scan was performed as previously
described (Gretarsdottir et al. 2002), with a framework scan of
microsatellite markers. We used multipoint, affected-only allele-
sharing methods (Kong and Cox 1997) to assess the evidence for
linkage. All results were obtained using the program Allegro
(Gudbjartsson et al. 2000) and our genetic map (Kong et al. 2002).
We used the Spairs scoring function (Whittemore and Halpern 1994;
Kruglyak et al. 1996) and the exponential allele-sharing model (Kong
and Cox 1997) to generate the relevant 1 df (degree of freedom)
statistics. When combining the family scores to obtain an overall
score, instead of weighting the families equally or weighting the
affected pairs equally, we used a weighting scheme that is halfway
between the two in the log scale; our family weights are the geometric
means of the weights of the two schemes. This weighting scheme
tends to give results similar to those of the scheme proposed by
Weeks and Lange (1988) as an extension of a weighting scheme of
Hodge (1984) designed for sibships.
We computed the p value two different ways and report the less
signiﬁcant one. The ﬁrst p value was computed based on large sample
theory: Zlr ¼ =[2 loge(10)LOD] is approximately distributed as a
standard normal random variable under the null hypothesis of no
linkage (Kong and Cox 1997). Because of the concern with small
sample behavior, we computed a second p value by comparing the
observed LOD score to its complete data-sampling distribution under
the null hypothesis (Gudbjartsson et al. 2000). When a dataset consists
of more than a handful of families, which is the case here, these two p
values tend to be very similar. To ensure that the result was a true
reﬂection of the information contained in the material, for us to
consider a linkage result signiﬁcant, not only was it required that the
p value be smaller than 2310
 5 (Lander and Kruglyak 1995), but also
that the information content in the region was at least 85%. The
information measure we used has been deﬁned previously (Nicolae
1999) and implemented in Allegro. This measure is closely related to
a classical measure of information (Demster et al. 1977), having the
property that it is between 0, if the marker genotypes are completely
uninformative, and 1, if the genotypes determine the exact amount of
allele sharing by descent among the affected relatives.
Adjustment for relatedness of the affected. Fortheassociationtests
performed for the Ser37Ala variant, if we do not adjust for the familial
relationships among some of the affected, the p values are anti-
conservative, but the estimated RRs are not biased because one can
considertherelatednessashavinganeffectonthevariancebutnotthe
mean of a test statistic. To address this issue, we extended a variance
adjustment procedure described in Risch and Teng (1998) for sibships
so that it can be applied to general familial relationships. Speciﬁcally,
based on the familial relations known about the patients, we ﬁrst
calculated the inﬂation factor, relative to having unrelated patients, of
the variance of the test statistic, deﬁned as the difference between
haplotype frequencies in the patients and controls. The p value
obtained from the Fisher’s exact test, assuming that the patients are
unrelated, was converted to a corresponding 1 df v
2 statistic that gives
the same p value. This v
2 statistic was then divided by the inﬂation
factor to obtain the adjusted v
2 statistic and the adjusted p value.
Haplotype analysis. To handle missing genotypes and uncertainty
withphase,weutilizedNEMO(Gretarsdottiretal.2003),ourhaplotype
analysis program, in which we implemented a likelihood procedure,
using the expectation–maximization algorithm as a computational
tool, to estimatehaplotype frequencies. Under the null hypothesis, the
affected individuals and controls are assumed to have identical
haplotype frequencies. Under the alternative hypothesis, the candi-
date at-riskhaplotype is allowedto have a higherfrequency in affected
individuals than controls, while the ratios of the frequencies of all
other haplotypes are assumed to be the same in both groups.
Likelihoods are maximized separately underboth hypotheses, and a
corresponding 1 df likelihood ratio statistic is used to evaluate
statistical signiﬁcance, a method we have used previously (Stefansson
et al. 2002; Gretarsdottir et al. 2003).Even though we only searched for
haplotypes that increase risk, all reported p values are two-sided for
the Icelandic data, but they have not been adjusted for multiple
comparisons or for the relationships of some of the Icelandic patients,
except for the Ser37Ala variant. However, the p values for the
replication study performed with the Danish cohort are one-sided.
LD mapping. In order to study the LD with microsatellites, an
extension to the deﬁnitions of D9 (Lewontin 1964) and its statistical
signiﬁcance for bi-allelic markers were utilized. The extended D9 is
averaged over all the possible allele combinations of the two markers
D9, weighted by the marginal allele probabilities (Hedrick 1987). The
corresponding p value is deﬁned as the minimum p value for the pair
of markers over the same combinations, provided the joint
probability is higher than 0.05. Plotting for all marker combinations,
D9 in the upper-left corner and the p value in the lower-right corner
suggest the LD structure of the region (see Figure 4B).
SNP identiﬁcation and genotyping. We screened all exons in the
entire region of interest (1.7 Mb), both in known genes (BMP2, CHGB,
LOC51605, C20orf154, C20orf155, and C20orf42) and in regions where
there was an mRNA (AY007089) or a spliced EST (AI971377,
BG822004), by direct sequencing from a PCR template. Subsequently,
we screened a 59 kb region containing the BMP2 gene by overlapping
PCR fragments. All exonic SNPs discovered were genotyped on the
entire material, patients, relatives, and controls, using a method for
detecting SNPs with ﬂuorescent polarization template-directed dye-
terminator incorporation (the SNP–FP–TDI assay) (Chen et al. 1999).
The Ser37Ala variant was genotyped by direct PCR sequencing since
a functional FP–TDI assay could not be made. Many of the nonexonic
SNPs were also genotyped on all the available material.
Screening for other genes than BMP2. The following ESTs were
investigated: AY007089, AI971377, BG822004, BF355539, BE145076,
AW852841, and AW852981, as well as several predicted genes/exons.
Gene prediction programs included GeneScan, MZef, GRAIL, FgSH,
HMMGene, Fgene, and Var3. Reverse transcription was performed
using Powerscript Reverse Transcriptase (Clontech, Palo Alto,
California, United States) and the ThermoScript RT–PCR system
(GIBCO–BRL, Carlsbad, California, United States) according to the
manufacturers’ protocols. Poly(A)
þ RNA from bone marrow (Clon-
tech) and total RNA from hFOB 1.19 (a human fetal osteoblastic cell
line from the American Type Culture Collection, Manassas, Virginia,
United States) were used for cDNA synthesis.
Supporting Information
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The LocusLink (http://www.ncbi.nlm.nih.gov/LocusLink/) accession
numbers for the genes discussed in this paper are BMP2 (LocusLink
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